44,247 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Bought by Blue Trust Inc.

Blue Trust Inc. purchased a new stake in shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 44,247 shares of the company’s stock, valued at approximately $185,000.

Separately, Magnolia Capital Advisors LLC purchased a new position in shares of DiaMedica Therapeutics during the second quarter valued at approximately $87,000. 10.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $6.00 target price on shares of DiaMedica Therapeutics in a research report on Friday, August 16th. HC Wainwright assumed coverage on shares of DiaMedica Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $7.00 price objective for the company.

DiaMedica Therapeutics Stock Up 1.3 %

Shares of DMAC stock opened at $4.39 on Friday. The business’s fifty day moving average is $4.18 and its 200 day moving average is $3.39. The stock has a market cap of $187.64 million, a price-to-earnings ratio of -7.84 and a beta of 1.48. DiaMedica Therapeutics Inc. has a twelve month low of $2.05 and a twelve month high of $4.95.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same quarter in the prior year, the business earned ($0.16) earnings per share. Equities research analysts expect that DiaMedica Therapeutics Inc. will post -0.58 earnings per share for the current fiscal year.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.